

RD FY22 Workplan

The Registration Division (RD) of the Office of Pesticide Programs fulfills its mission to protect public health and the environment by using the best science and regulatory approaches in the registration of conventional pesticide products, authorization of emergency exemptions and approval of inert ingredients.

RD, under the statutory authority of FQPA, FIFRA and PRIA, establishes pesticide tolerances for conventional chemicals, registers new active ingredients and products, approves use expansions, product amendments, notifications and inerts, as well as authorizes Section 18s and 24(c)s. In addition, RD handles all in processing of actions, as well as distributor products and company transfers.

RD has developed the following Fiscal Year Work Plan for FY22. This Plan covers a wide range of topics and lays the goals for the division. This work plan provides a detailed listing of specific accomplishments for which RD has the lead as well as other projects jointly managed with other OPP divisions. RD will use this plan to establish targets and report on progress throughout the year. This is a living document and will updated as priorities shift.

Results Driven

FQPA, FIFRA and PRIA are the statutory authorities that guide risk management/assessment decisions for new pesticides, use expansions, new products, product amendments, notifications, re-evaluations, inerts, Section 18s and 24c. 97% of all PRIA actions will be completed within the PRIA timeframe. RD will monitor and work towards reducing the renegotiation rate by at least 5%. The RD management team will manage toward reducing the non-PRIA backlog for actions by at least 25%. Global joint reviews and work shares will be encouraged when appropriate. The division is responsible for leading initiatives on process improvements that result in more efficient/effective decision-making. RD is also responsible for providing support to Office of General Counsel on litigation and supporting audits/evaluations and implementing corrective action.

Division Projections for FY22

PRIA Actions	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
New Chemical Registrations	1		0		5		2		8	
New Chemical Import Tolerances	2		1		0		0		3	
New Uses for Existing Chemicals (count of use sites, not OPPIN decisions)	60		59		30		33		182	
PRIA New Products and Amendments	224		197		178		179		778	
Exclusive Use	0		1		1		1		3	
Non-PRIA Decisions ¹	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Fast Track Label Amendments	111		123		121		120		475	

¹ RD is starting the FY with a significant backlog of fast-track amendments and notifications. These projections do not include the actions that are under the purview of the Tiger Team.

Notifications	154		150		160		157		621
Minor Formulation Amendments	35		35		34		34		138
Emergency Exemptions (Section 18s)	15		10		30		20		75
Special Local Need Registrations (Section 24(c))	30		50		55		65		200

Efficacy Reviews	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Invertebrate PRIA	12		6		8		14		40	
Invertebrate Non-PRIA	1		1		X		X		2	
Vertebrate	1		4		2		1		8	

Inert Ingredient PRIA Decisions	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Food Use Petitions	5		6		5		6		22	
Non-Food Uses	4		5		4		5		18	

Chemistry and Tox Review	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Chemistry	180		180		180		180		720	
Acute Toxicity	125		125		125		125		500	

Gold Seals	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
Gold Seals	19		19		19		19		76	

Results Driven

ISB	Q1		Q2		Q3		Q4		Totals	
	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual
6(a)(2) Submissions	225		225		225		225		900	[See Narrative]
6(a)(2) Major Incidents Processed	900		850		925		900		3575	
Supplemental Distributor	420		546		508		360		1834	
In- Process Submissions via the PSP	2700		3000		2200		3000		10900	
In Processing Applications via New PRISM/Sales Force	800		1025		900		900		3625	
Fee Waivers	140		150		120		90		500	
Company Name/Address Change	60		55		60		80		255	
Transfers	30		25		30		25		110	
Maintenance Fee Processing	100		1200		400		0		1700	
Refunds	50		50		70		50		220	

FY22 Conventional Chemical New Active Ingredient Workplan

Chemical	PRIA Due Date	Original PRIA Due Date	Uses	Q1	Q2	Q3	Q4
Pyflubumide	12/20/21	12/20/21	import tolerance only on tea, dried, and tea, instant	Publish final rule			
Spiropidion	8/5/22	8/5/22	Multiple Crops	Monitor Progress of reviews	Discuss continued review process with risk assessors	Initiate Public Process	Issue Registration
Reklamel	1/4/22	4/18/21	CG9; CG8-10; CG10-10; CG12-12;CG14-12; CG13-07F; CG1C				Issue FRN (completion pending ESA)
Ipflufenquin	10/29/21 (pending negotiation to 1/29/2022)	4/19/2021	Pome fruit, almond	Work through comments from CBD on ESA	Publishing of tolerance rule, RTC, Final Decision, and registration expected in Q2		
Pyraziflumid	12/13/21		Uses include stone fruit, pome fruit, caneberry, bushberry, kiwi fruit, tree nuts, turf	Meet with company to discuss findings, data needs; discuss with company date for response; determine mitigation			

[PAGE * MERGEFORMAT]

Chemical	PRIA Due Date	Original PRIA Due Date	Uses	Q1	Q2	Q3	Q4
				options, Follow up with on mitigation options; DD briefing			
Isoprothiolane	10/12/21		Banana (i), rice (i)	RD/IO signature	Publish final rule		
Florylpicoxamid Reduced Risk	4/27/22	10/27/21	Barley, rapeseed, wheat, sugar beet, dried peas/beans. Nonfood use: turf.				
L-glufosinate (Ammonium) Reduce Risk	4/12/22	10/22/21	Enriched isomer, no change in existing tolerances				
L-glufosinate (Acid)	6/13/22	12/13/21	Enriched isomer, no change in existing tolerances				
Pyraclonil	5/23/22	11/22/21	Rice (California only)	resolution			
Diflufenican Workshare with PMRA		9/19/22	Pre-plant and pre-emergence use on soybeans and corn.				

FY22 New Uses (significant new uses (i.e., in RD WP) are subject to public process, responding to critical pest needs, or other public interest)

In RD WP? (y/n)	Chemical	PRIA Due Date	Original PRIA Due Date	Uses	Q1	Q2	Q3	Q4
y	Cyclaniliprole, Flonicamid	2/17/22	10/21/19	first outdoor residential use		Issue registrations		
y	Pyriproxyfen	3/11/22	11/12/21	1st outdoor residential/non-ornamentals				
y	Flonicamid/ Cyclaniliprole	2/17/22	11/19/21	1 st outdoor residential/non-food ornamentals				
Y	Oxytetracycline	12/30/2021 delayed	4/9/2018	Antibiotic; Cherry	Get input from ORD			
Y	Oxytetracycline	03/14/2022 delayed		Antibiotic; Walnut, Olive	Get input from ORD			
Y	Kasugamycin	12/5/2022		Antibiotic; Olive	Review ARRT review, BEAD review, EFED review			
Y	Kasugamycin	4/1/2022	10/2/2020	Antibiotic; Peach subgroup 12-12B, Apricot, Almond	Proposed decision in Team Review, OGC review, RD/IO Publishing of proposed decision expected in Q1.		Publishing of tolerance rule, RTC, Final Decision and registration.	

[PAGE * MERGEFORMAT]

In RD WP? (y/n)	Chemical	PRIA Due Date	Original PRIA Due Date	Uses	Q1	Q2	Q3	Q4
Y	Chlormequat Chloride	2/22/2022		First food uses; Wheat, Triticale, Barley, Oats, and Grasses Grown for Seed	Proposed decision for Branch review, Team review,	Proposed decision for OGC review, Publish proposed decision	Publish final decision, Final Rule	
Y	Benzovindiflupyr	12/28/2021	3/8/2021	First residential uses; athletic fields, residential lawns	Publish proposed decision for RD/IO review, signature by IO	Publish final decision		
Y	R350 Not a NU Isoxaflutole GMO; ESA	1/28/22		Cotton			x	

FY22 Significant New Uses Tolerance rules submitted by IR-4 (tag other branch)

In RD WP? (y/n)	Branches	Chemical	PRIA Due Date	Original PRIA Due Date	Uses	Q1	Q2	Q3	Q4
y	IVB3, MUERB	Fluensulfone	11/1/2021	10/1/2021	0 new uses (crop group conv only)	Publish final rule			
y	FB, MUERB	Cyprodinil	TBD	11/4/2021 (will renege)	1 new use (sugar apple) + 2 cg		Publish final rule		

					expansions (sg 10-10B; 24A) + cg conv				
y	FB, MUERB	Fludioxonil (different than Tony's list, which has 6 new uses + 4 for the R298 PRIA codes)	TBD	11/4/2021 (will renege)	9 new uses (sugar apple; dragon fruit; Japanese persimmon, jackfruit, durian & mangosteen; greenhouse cucumber, greenhouse pepper; greenhouse tomato) + 3 cg expansions (sg 20C; 20B; 24A) + cg conv		Publish final rule		
Y?	FB (bundled with IR-4)	Fludioxonil	TBD	11/1/2021 (will renege)	2 new uses (group 14-12, which has 2 rep crops)		Publish final rule		
y	FHB, MUERB	Propamocarb hydrochloride	11/16/2021	8/18/2021	2 new uses (group 5-16, which has 2 rep crops)	publish final rule			
Y	IVB1, MUERB	Bifenthrin	11/22/2021	2016	5 new uses (avocado; pome fruit 11-10, which has 2 rep crops; peach; pomegranate) + 4 CG expansions (sg 13-07G, 13-07F, 8-10A, 8-10B)	Publish final rule			
Y?	IVB1 (bundled with IR-4)	Bifenthrin	11/22/2021	2019	1 new use (sunflower sg 20B)	Publish final rule			
Y	FHB, MUERB	Glufosinate	12/3/2021	12/3/2021	7 new uses (sg 8-10A, 8-10B, 9A, 9B, fig, avocado, hops) + 5 cg expansions (sg 20A,	Publish final rule			

					20C, 13-07F, 23A; 1C) + cg conv				
Y	FHB (bundled with IR-4)	Glufosinate	12/3/2021	??	1 new use (cotton gin by-products; also includes sg 20C, which is counted for the IR-4 petition)	Publish final rule			
Y	IVB2, MUERB	Cyflumetofen	12/27/21	12/27/21	1 new use (hops)	Publish final rule			
N	FB, MUERB	Oxytetracycline	12/30/21	2018	2 new uses (cherry, sweet and cherry, tart)	Renegotiate PRIA date			
Y	HB, MUERB	MCPA	1/5/2022	1/5/2022	1 new use (clover)	Publish final rule			
y	IVB2, MUERB	Buprofezin	1/31/2022	7/22/2021	1 new use (sg 13-07B) + cg expansion to sg 6- xxA (1 future sg = 25 individual commodities)		Publish final rule		
y	FB, MUERB	Ethaboxam	2/22/2022	2/22/2022	3 new uses (sg 4-16B; group 5-16, which has 2 rep crops)		Publish final rule		
Y	IVB2, MUERB	Methoxyfenozide	2/28/2022	8/30/2021	3 new use (rice grain, hull & straw) + 3 cg expansions (sg 20C; 23C; 24A) + cg conv including 6 future subgroups in 6-xx = 118 individual beans & peas)		Publish final rule		
Y	HB, MUERB	Ethalfuralin	3/4/2022	3/4/2022	2 new uses (stevia, hemp) + 3 cg expansions (sg 1C, future sg 6-xxE = 48			Publish final rule	

					indiv beans; future sg 6-xxF = 8 indiv peas)				
Y?	HB (bundled with IR-4)	Ethalfuralin	9/16/2022	9/16/2022	1 new use (sg 3-07A)			Publish final rule	
N	FB, MUERB	Oxytetracycline	3/14/2022	3/14/2022	2 new uses (olive, walnut)		Renegotiate PRIA date		
Y	IVB2, MUERB	Novaluron	3/21/2022	3/21/2022	4? New uses (future sg 6-xxB = 9 indiv peas; future sg 6-xxD = 6 indiv peas; future sg 6-xxF = 8 indiv peas; pea forage) + 3? cg expansion (future sg 6-xxA = 25 indiv beans; future sg 6-xxC = 22 indiv beans; future sg 6-xxE = 48 indiv beans)		Publish final rule		
Y?	IVB2 (bundled with IR-4)	Novaluron	3/21/2022	1/10/2022	2 new uses (group 14-12, which has 2 rep crops)		Publish final rule		
Y	FB, MUERB	Kasugamycin	4/1/2022	10/2/2020	3 new uses (almond, apricot, sg 12-12B)			Publish final rule	
Y	FHB, MUERB	Mandestrobin	4/4/2022	4/4/2022	1 new use (lettuce)			Publish final rule	
Y?	FHB (bundled with IR-4)	Mandestrobin	6/30/2022	6/30/2022	2 new uses, both on sg 20A – foliar & seed treatment			Publish final rule	
Y	FB, MUERB	Pyriofenone	4/26/2022	4/26/2022	2 new greenhouse uses (cucumber and sg 8-10B). There is also a new GH use on sg 8-10A, but it is an R350			Publish final rule	

					and associated with the end use product, not this petition				
Y	FB, MUERB	Sulfur dioxide	5/23/2022	5/23/2022	1 new use (blueberry)			Publish final rule	
Y	FHB, MUERB	Tribenuron-methyl	6/14/2022	6/14/2022	2? New uses (future sg 6-xxE = 48 indiv beans; future sg 6-xxF = 8 indiv peas) + 7? cg expansions (sg 20A, 20C; future sg 15-xxA = 31 indiv [wheat] crops; future sg 15-xxB = 9 indiv [barley] crops; future sg 15-xxC = 3 indiv [corn] crops; future sg 15-xxE = 11 indiv [sorghum/ millet] crops; future sg 15-xxF = 4 indiv [rice] crops)			Publish final rule	
Y	IVB1, MUERB	Cyclaniliprole	6/22/2022	6/22/2022	4 new uses (globe artichoke, sg 20B, greenhouse sg 8-10A, greenhouse sg 8-10B)			Publish final rule	
Y	FHB, MUERB	Fluazifop-p-butyl	7/5/2022	7/5/2022	6 new uses (sg 4-16B; group 5-16 (which has 2 rep crops); sg 22B; chive, papaya) + revised tolerance on green onion + 1 cg expansion (sg 13-07G) + cg conv				Publish final rule

Y	FHB, MUERB	Propiconazole	7/18/2022	7/18/2022	2 new uses (group 5-16, which has 2 rep crops)				Publish final rule
Y	FB, MUERB	Isofetamid	8/2/2022	8/2/2022	1 new use (ginseng) + 6? cg expansion (6 future subgroups in 6-xx = 118 indiv beans & peas)				Publish final rule
Y	HB, MUERB	Pronamide	8/19/2022	5/20/2019	1 new use (sg 13-07H [cranberry]) + 4 cg expansions (11-10; sg13-07A; 13-07B; 13-7F) + cg conv		Contact HED & PRD on status of Reg Review studies		Publish final rule?
Y	FB, MUERB	Pydiflumetofen (different than Tony's list, which has 1 new use total)	9/22/2022	9/22/2022	2 new uses (sg 13-07A; greenhouse 8-10) associated with the petition. Also includes a new greenhouse lettuce use, which is an R350 associated with the end use product				Publish final rule

FY22 Additional Significant Projects

In RD WP?	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB3 Ricardo Jones, Acting Venus Eagle, Marianne Lewis	Sulfoxaflor litigation support: During oral arguments in Oct 21' EPA agreed to complete ESA assessment by Spring 22'	Once draft ESA is available, discuss potential pre-mitigation with Corteva	EFED completes draft ESA overview	Plan to brief AA on mitigation/response options	

In RD WP?	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	Cynthia Giles-Parker, Stephanie Suarez Manju Unnikrishnan and Rachel Holloman	Lawsuits: Litigation support for inpyrfluxam CBD, CFS vs EPA Lawsuits - Trifludimoxazin CBD and CFS requesting ESA review, and Bicyclopyrone requesting ESA review.	Work with OGC and senior management as needed			
Y	Ethan Harwood, Stephanie Suarez	Litigation support for streptomycin Migrant Clinicians Network, et al vs EPA				
y	IVB3 Ricardo Jones, Acting Venus Eagle, Gene Benbow, Scott Campbell, Paul DiSalvo, Marianne Lewis	Response to Data Compensation Petitions to Deny: Petition from BASF regarding pending Clothianidin/Sharda action; petition from Bayer regarding pending Spirodiclofen/Sharda action.		Responses drafted, briefing if necessary	Complete PRIA actions (if resolved)	
Y	Ethan Harwood, James Orrock, Elisha Graham, Carmen Rodia	Response to Data Compensation Petitions to Deny: Petition from BASF to deny support for pyraclostrobin BASF vs Sharda and petitions from Bayer vs Sharda Life Scientific and ADAMA	Meet w/OGC, work through data citations			
Y	Shaja Joyner, Manju Unnikrishnan, Nate Mellor, Francisco LLarena-Arias, Marc Sheahin, Lindsay	Response to Data Compensation Petitions to Deny: There are five currently active high-profile petitions to deny. This work is in response to a registrant concern associated the data compensation. The active ingredients	Working to complete all 5 petitions to deny with the help of OPS and OGC.			

In RD WP?	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
	DeMers, and Rachel Holloman	include: boscalid, pinoxaden, fenoxaprop, glufasinate, diuron.				
y	IVB3 BC, Paul DiSalvo, Scott Campbell, Gene Benbow	Non-data comp Petition Responses: Includes feral horse contraceptives and feral swine		Response to feral swine issued		Response to feral horse issued
y	Balan, Aswathy Joyner, Shaja Holloman, Rachel	New AI SOP in response to IG report Draft for review	December 30, 2021 November 23, 2021			
y	Meg, Mindy, Curtis	Enlist renewal action. Impacts resistant corn, soy and cotton. Pioneering ESA action.	Issue registration and begin consultation			
y	Meg, Emily, Sarah, Lydia	Dicamba action following information gathered about the last growing season. This decision could have a large impact on GMO crops across a large portion of the US.	Complete review of 2021 incident information	Regulatory next steps	TBD	TBD
y	PMs, BC, all staff	Prioritize petitions to deny new products in order to address those in as close a timeline as possible to the PRIA timeline. Do not register any product for which a petition to deny is still pending. Currently one petition to deny with HB (Glyphosate (Bayer/Willowood))				

Other Results Driven Projects

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB1, IVB2, IVB3, FB, HB, FHB, IO Bo Davis, staff	NonPRIA Backlog Tiger Team: The Tiger Team, created from volunteers from the product branches, was created to help address the backlog of non-PRIA actions and provide useful training for new hires. Goals are for the whole team.	66 6 actions per person (1 action every 1 to 2 weeks)	66	66	66
y	IVB1 Jenn Saunders, Jackie Herrick, Jamey Shuler, Liz Andrews	Seresto 6(a)2 data review: Due to a high number of pet incidents submitted for Seresto, in FY21 RD requested additional information from Elanco and the previous registrant Bayer under FIFRA Section 6a2 on pet incidents, incident analyses submitted to other regulatory bodies, pharmacovigilance programs, and sales data, in addition to incident rates for other Elanco owned products, Advantage II and K9 Advantix. The team is coordinating the science review effort, after which a regulatory decision will be made.	Brief DDs on progress Establish a review timeline, in conjunction with tech lead			Receive science review
Y	Yasmin Bowers	Environmental Justice (EJ) Work Group - Member representation from each division are currently working on the workplan to incorporate the principles of EJ into OPP. The workplan and action				

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
		items will be planned out to be accomplished by FY22.				
y	MUERB (lead) Eric Bohnenblust, Tawanda Maignan Andrea Conrath, AD, BPPD, PRD	24(c) Audit: This work will respond to an IG audit and improve process surrounding review of 24(c) SLNs	1. AAPCO solicitation on guidance 2. SOP 3. Uploading to PPLS		Analysis of 24c review over the last 12 months.	
y	Meg Hathaway Eric Bohnenblust ERT team leader HB MUERB	Support the states as they roll out and enforce new dicamba OTT labels Collaborative work with state lead agencies – support transition to 24-c and 24a statutory compliance	Full SFIREG Consult with states/AAPCO		Review/consider dicamba 24(c) s if appropriate	

Additional Results Driven Standing Work

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
y	IVB1, IVB2, IVB3 Jennifer Saunders, Kevin Ulrich	Pesticide Efficacy Review Committee (PERC): PERC provides leadership and promotes high scientific standards and state-of-the-art approaches to insecticide/repellent efficacy evaluations and includes members from multiple OPP divisions. The committee is responsible for reviewing all invertebrate efficacy protocols and rebuttals and addressing invertebrate-related questions from OPP. All division efficacy reviewers attend the weekly PERC meetings and serve as notetakers and designated reviewers for protocols and rebuttals brought through the workgroup.	
y	IVB1, IVB3 Ricardo Jones, staff	Vertebrate Efficacy Review Committee (VERC): VERC is comprised of scientists with expertise in vertebrate pesticide efficacy data review. Standing work includes weekly meetings and answering vertebrate efficacy-related questions from OPP.	
y	IVB1, IVB2, IVB3, FHB, FB Marion Johnson, staff	Child Resistant Packaging (CRP) Committee: Housed in both the Registration Division (RD) and Antimicrobials Division (AD), this committee provides leadership and promotes high regulatory standards of CRP evaluations. The Committee is responsible for reviewing all CRP studies and certifications and addressing all child resistant packaging inquiries from the OPP divisions, registrants, child resistant packaging professionals, state regulatory officials, other government agencies and the public.	

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
Y	Reduced Risk Nate Mellor	The purpose of the Reduced Risk Committee is to encourage the chemical/use pesticide that is less risky than what is currently on the market, Incentives includes lower PRIA fees, less review time and the ability to include Reduce Risk EPA designation in registrant marketing materials.	All year long announcement for an opportunity to become the new coordinator will go our December or January
Y	Manju Unnikrishnan and Rachel Holloman	Lawsuits - Trifludimoxazin CBD and CFS requesting ESA review, and Bicyclopyrone requesting ESA review.	Work with OGC and senior management as needed
Y	Mick Yanchulis – Brenda Minnema; Tiffany Tran (contractor)	Yearly product maintenance fee collection -	further streamline the maintenance collection process -possible implementation into New PRISM/Sales Force. Respond to annual FIFRA audit

Leading Change

The RD management team effectively initiates and manages change by assessing and adjusting to changing situations, implementing innovative solutions to make organizational improvements, ranging from incremental improvements to major shifts in direction or approach, as appropriate. The team balances change and continuity; continually strives to improve service and program performance; creates a work environment that encourages creative thinking, collaboration, and transparency; and maintains program focus, even under adversity. RD advances EPA's Lean Management System to accomplish the FY18-22 Transformation Strategy and is responsible for deployment of ELMS in accordance with the schedule developed in consultation with the Office of Continuous Improvement.

Leading Change Projects

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB1, IVB2, IVB3, MUERB Jennifer Saunders, Eric Bohnenblust, Dee Colby, Virna Stillwaugh, PERC	Efficacy Guidelines and Rules: OPP is wrapping up a >10 year effort to publish a rule on the invertebrates for which efficacy data submission are required and the corresponding product performance standards. RD and BPPD are also working on updating the mosquito, tick, and termite guidelines to increase clarity on study methodology best practices and to decrease the number of protocols, rebuttals, and additional studies needed.	Brief AA on PP rule ✓ Establish revised project plan and timeline for mosquito/tick and termite guidelines✓		Publish PP rule	
y	IVB1, IVB2, IVB3 Jennifer Saunders, Marion Johnson, Ricardo Jones, Beth	Spot on conversions: Spot on registrants who submit their enhanced incident data using the Agency-preferred template correctly can have their registrations' time-limitations removed and their enhanced reporting requirements	1 (IVB1)✓ 1 (IVB2)	4 (IVB1) 1 (IVB2)	5 (IVB1) 1 (IVB2)	

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
	Fertich, Venus Eagle, Mike Walsh	changed from quarterly to annual reporting, which requires a review by HED for acceptability of the template, a branch review of the labeling and CSFs, and the issuance of a registration letter outlining the new conditions of registration. Using the template is particularly important because it will allow the Agency statisticians to easily compare data across products. Projected number of conversions are listed to the right.				
y	IVB1, IVB3 Jennifer Saunders, Autumn Metzger , Dee Colby, Virna Stillwaugh	New Approach Methodologies (NAMs): RD is working with PETA to produce a live 2-day workshop in FY22 on alternatives to animal testing for efficacy studies. Participants will include NGOs, academics from around the world, other government agencies (FDA, USDA), and industry. The team is also producing a fall webinar series, which will include 3-4 webinars on the current state of the science.	Give webinar on current EPA efficacy testing v (Autumn Metzger)	Provide support for upcoming workshop	Co-host workshop on NAMs and efficacy testing (see leads)	
y	IVB1, IO Jennifer Saunders, Paul DiSalvo	Renegotiation SOP: The renegotiation SOP will be revised to include current best practices and examples of appropriate language for common causes of renegotiations.		Finalize revised SOP		

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	Eric Bohnenblust, ERT Team Leader, Andrea Conrath	COVID Response Efforts: Working with AD, BEAD and the states evaluate products that may support the EPA's COVID response	PIVOT for all COVID 18s Support OECA and Region in criminal case against ABS for SW2 Grignard VA Honeywell – NC, TX Acteev facemask - TX			
Y	MUERB, IVB2, HB Eric Bohnenblust Nancy Fitz, Debra Rate, Mindy Ondish	Hemp: With HED, OGC and others work up the data needs, risk assessment approaches and regulatory strategy for supporting conventional pesticide uses on hemp crops, 24c piece	Receive RAs for Ethalfluralin from Science Divisions		Ethalfluralin PRIA Date is March, but likelihood of renegotiation	
Y	MUERB, IVB2, HB Eric Bohnenblust Nancy Fitz, Debra Rate, Mindy Ondish	Advance crop group scheme – (1) implement the new Phase VI rule	Publish proposed Phase VI rule			Publish Final Phase VI rule
Y	Acute tox/waiver requests and evaluation of	New Assessment Methodologies (NAMs) RD will take tangible steps in FY21 to support the scoping, development, and	Facilitate Meetings and Seminars with external	Facilitate Meetings and Seminars with external	Develop draft guidance/policies regarding use of alternative acute	Brief RD IO on draft guidance/policies regarding use of

[PAGE * MERGEFORMAT]

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
	alternative test methods: Kerry Leifer , Julie Breeden-Alemi Lead	execution of New Assessment Methodologies (NAMs): <ul style="list-style-type: none"> Lead and track pre-submission meetings with registrants and encourage the submission of waiver requests where appropriate Track and report the number of acute toxicity waiver requests received and approved. Evaluate alternative test methods for acute toxicity endpoints 	stakeholders and experts on use and applicability of NAMs for acute toxicity endpoints	stakeholders and experts on use and applicability of NAMs for acute toxicity endpoints	toxicity testing for conventional chemical pesticide products	alternative acute toxicity testing for conventional chemical pesticide products
Y	Kerry Leifer , Shyam Mathur, Product Chem. Team	Product Chemistry Self-Certification <ul style="list-style-type: none"> Increase registrant usage of chemistry certification under PR Notice 98-1 Work to develop expanded product chemistry self-certification program 	Develop processes to efficiency capture number of product chemistry submission currently utilizing self-certification	Calculate % of actions that use product chem self-certification. Determine if changes to current self-certification language is appropriate	Expand pilot process for expansion of self-certification	
Y	Kerry Leifer , Evisabel Craig	PFAS <ul style="list-style-type: none"> Assess Inert Ingredients to confirm those that may have PFAS structures Identify usage in pesticide products 	Identify inert ingredients that may meet OPPT or OECD PAFS definition	Determine extent of use of any PFAS inert ingredient in pesticide products by evaluating	Remove any PFAS inert not currently in use from listing of approved inert ingredients. Explore options	Work with registrants to remove/replace PFAS inerts from products

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
		<ul style="list-style-type: none"> Take steps to reduce or eliminate use where practicable 		actual product CSF information	for removing PFAS inerts from pesticides	
Y	ISB Branch Chief Raderrio Wilkins Lee Sias Mick Yanchulis	Front-end processing 21-day screen implementation in New PRISM/Sales Force (AD/BPPD)	<p>Oversee training of MERP contract staff on completing the g 21-day content screen review in New PRISM/Sales Force</p> <p>Implement 21-day review process into New PRISM/Sales Force for AD/BPPD.</p> <p>Review 21-day content screen form for inclusion of additional tracking metrics/dates</p> <p>Review Contractor Performance on new process</p>	<p>Update 21-day content screen form to include additional tracking metrics/dates</p> <p>Review Contractor Performance on new process</p>	<p>Further revisions to 21-day content screen form to include additional tracking metrics/dates</p> <p>Review Contractor Performance on new process</p>	Review Contract Performance on new process

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4

Additional Leading Change Standing Work

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
y	IVB1, IVB2, IVB3, HB, FB, FHB Rachel Holloman, Jennifer Saunders	ELMS New Ais: RD has been using the EPA Lean Management System process to track progress on its new active ingredients. Standing division work includes holding weekly huddles, updating proxy cards and tick sheets, and periodically assessing reasons for delay to determine if any trends exist and can be addressed.	
y	IVB1, IVB2, IVB3, HB, FB, MUERB Jennifer Saunders	Process Improvement Team: RD is establishing a new team to track and facilitate process improvements. This FY, the group will be formed, its mission and related processes will be established, and ongoing process improvements will be tracked.	
	75-Day Letter Revisions Emily Schmid Cynthia Giles-Parker Marion Johnson	This additional clarification to an existing policy will assist in preventing unnecessary rework and low-quality resubmitted material from registrants. More efficient use of agency limited resources is expected.	Targeted completion and implementation. Update templates, outreach, website updates

Leading People

Carries out supervisory/managerial duties in accordance with federal regulations and EPA policies within established deadlines to provide direct reports with leadership and direction to support RD and EPA in meeting its mission, goals and objectives. Effectively: Considers employee and customer feedback; Recruits and selects qualified employees; Recognizes and awards employees; Manages employees' performance and takes appropriate action when performance or conduct issues arise; Provides training and mentorship to employees; Promotes an environment encouraging staff engagement; Manages budget provided; Promotes diversity, inclusion and equal employment opportunity; and Resolves conflict, discrimination or harassment in the workplace.

Leading People Projects

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB1, IVB2, IVB3, FB, HB, FHB, MUERB, ISB, CITAB, IO All supervisors	All supervisors are expected to have staff meetings, general meetings, set priorities, develop staffing plans, establish PARS, monitor progress towards goals, address performance/conduct issues.	Establish PARS RD priority setting Quarterly all-hands meeting Weekly staff meetings, regular generals	Mid-year PARS RD priority setting Quarterly all-hands meeting Weekly staff meetings, regular generals	Process timeoff/cash awards RD priority setting Quarterly all-hands meeting Weekly staff meetings, regular generals	End of year appraisals RD priority setting Quarterly all-hands meeting Weekly staff meetings, regular generals
	FB, FHB, CITAB, IVB3, HB, IO Rachel Holloman (advisor)	RD Training Program (New Hires, et. al.) Recurring • The RD training team developed and maintains a training SharePoint site (centralized location for staff to access OPP training presentations)	Bo (IO) start attending meetings Weekly meetings with Bo and Kerry	CSF step-by-step Meet with Bo to ensure that the training team initiatives are in	Weekly meetings with Bo and Kerry to cover CSF questions	Weekly meetings with Bo and Kerry to cover CSF questions

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
		<p>for all staff in RD. This site provides information for on-boarding new staff, provides a supervisory toolkit and other important information for staff. It also includes the "welcome buddy" assignment position to facilitate the integration of new hires into RD.</p> <ul style="list-style-type: none"> • To issue Presubmission checklist this year. • To post CSF step-by-step from the RM viewpoint with screen shots • Enhance Tiger Team experience by giving step-by-step written instructions for doing a 345 with help from Bo and Kerry • New employees meet and greet. 	to cover CSF questions	<p>line with the overall RD Training Plan</p> <p>Weekly meetings with Bo and Kerry to cover CSF questions</p>		
y	MUERB, Nancy Fitz, ERT	Training for RD – FR training, Section 18/24(c) training (coordinate training plan for division)	FR training	Section 18/24(c) training		

Additional Leading People Standing Work

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
Y	Debra Rate, and others	Device Determinations – Representative for OPP Workgroup devoted to facilitating the determinations for Senior Management concurrence of proposals to the agency that may be exempt from pesticide registration.	
Y	Betty Williams/Marion Johnson (BC)	FIFRA CBI, Ethics Coordination – Ongoing requirements where increased timeliness of response and monthly review/reporting as efficiency tools are needed.	

Building Coalitions, Networking and Communication

Through its leadership, the RD management team actively works to meet the needs of the customer (external and internal) to the extent feasible by keeping open lines of communication, working to inform and involve all interested parties and delivering products and services when promised. The RD management team considers feedback from internal and external stakeholders and/or customers. The team maximizes input from the widest range of appropriate stakeholders to facilitate an open exchange of opinion from diverse groups and strengthen internal and external support. Each member of the RD management team expresses facts and ideas in a convincing manner and negotiates with individuals and groups internally and externally, as appropriate. The division develops a professional network with other organizations and identifies the internal and external politics that affect the work of the organization.

Building Coalitions Projects

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB1, IVB2, IVB3 Jennifer Saunders, Marion Johnson, Ricardo Jones	Scientific Meeting Attendance: RD hopes to attend and present at a number of relevant scientific conferences this fiscal year (one has been approved so far). RD uses these meetings as platforms to communicate relevant updates to the entomological community (e.g., the new guidelines and how to register novel vector control products) and to stay current on technical issues.	Present at Ent Soc meeting ✓	Attend AMCA Attend MAMCA	Present at National Conference on Urban Entomology and Invasive Pest Ant Conference	Present at ASPCRO Present at AVMA National Convention Present at International

[PAGE * MERGEFORMAT]

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
						Congress of Entomology
Y	Marcel Howard, Ethan Harwood	Pyraziflumid – pilot JR with PMRA- promote trade & prevent trade irritation	12/13/2021			
Y	MUERB Eric Bohnenblust, Nancy Fitz	IR4 Stoplight Analysis: EPA reviews the list of potential projects for IR4 and provides an indication of our ability to potentially grant the proposed new uses that would be supported by these projects	Smaller stoplight analysis			Full stoplight analysis with comprehensive list of projects
y	MUERB Eric Bohnenblust, Nancy Fitz	Hold biannual meetings with IR-4 to strengthen the organization effectiveness and to trouble shoot issues, crop tour?		Hold virtual TWG meeting in mid- Feb	Crop tour?	Q4: Hold TWG meeting in June or July; usually day before the IR-4 minor crop tour (if that happens this year) – scheduled for July 21
Y	Evisabel Craig, Inerts Team	Commodity Inert Ingredient List <ul style="list-style-type: none"> Evaluate additional candidates for inclusion on the Commodity Inert List Update List with new entrants Engage with stakeholders 	Identify all candidates for inclusion on Commodity Inert List	Prioritize candidates and initiate evaluation of top priority candidates	Update Commodity Inert List including OPP update	Further update Commodity Inert List

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	Kerry Leifer, Evisabel Craig	Inert Ingredient Supply Issues <ul style="list-style-type: none"> Work with stakeholders to identify significant supply chain issues Develop strategies to address supply issues (flexibilities in formulation, etc) within the existing regulatory structure 	Evaluate proposals from industry to continue/expand on the current "Phase 1 and Phase 2" regulatory relief initiatives	Determine if continuation or expansion of current relief is warranted. Provide determination to stakeholders and establish communication plan	Evaluate intermediate-term and long-term options for addressing supply chain issues	Develop options for addressing supply issues within the existing regulatory structure that can obviate short-term approaches
Y	IO Paul	Establish PRIA 5 Recommendations Need to reauthorize PRIA before FY23 and to update timeframes/fees and codes to better reflect work in RD	Meet with RD BCs, staff, and PRIA Ombudsman to discuss needs and develop wish list (October)	Establish polished list of PRIA 5 improvements (February)	Message with stakeholders on PRIA 5 desired changes (March)	Reach Congressional implementation of PRIA 5 (September)
Y	IO Paul, Dee, Marietta	FDA-EPA Jurisdictional Work for Pet/Livestock Products Determining better jurisdictional boundaries and collaboration between the two agencies.	Work on MOU draft categories (October to December) FDA-EPA Joint Briefing of Legal Options for Solomon-Messina (December)	Determine proposals for changes in PRIA 5 (February)	Finalize categories for MOU (June)	?

Building Coalitions

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	Catherine	Scoping for international discussion of data requirements (via OECD WPP)	Internal meetings	Internal and external meetings	Proposal development	Deliver proposal to OECD WPP

Additional Building Coalitions Standing Work

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
y	All branches Paul DiSalvo	RD Community Committee: The RD Community Committee devises and implements ways to further enhance the division's fun, inclusive, and welcoming nature, build on RD's team spirit, and recognize staff's hard work and dedication.	
y	HB Branch Chief and Curtis	Strengthening Weed Science Society of America (WSSA) collaboration: Touch base with WSSA liaison once quarterly. Work with liaison once per year to coordinate a presentation to RD and open to others in OPP as appropriate.	
Y	IO: Bo and Paul	Ombudsman Responsibilities This is role is important, since we answer questions from stakeholders, which helps to reduce the workload for the PMs.	An Ombudsman is available each day of the week.

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
Y	Catherine	Quarterly registration meetings with PMRA USMCA ExB and trilateral meetings	USA assumes chair of USMCA in FY22/23; will become lead for planning next trilateral meeting

Business Acumen

The RD management team assesses, analyzes, acquires, and administers human, financial, material, and information resources in a manner that instills public trust and accomplishes the organization's mission. The RD management team uses technology to enhance processes and decision making. Ensure proper execution of budget, IT, travel, training, and hiring. Promote, support and ensure compliance with EPA’s Scientific Integrity policy. As appropriate, sponsor LEAN events to promote increased efficiencies. Support OPP’s Digital Transformation Efforts.

Business Acumen Projects

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
y	IVB1, IVB3 Jennifer Saunders, Ricardo Jones	Workload Distribution: A workload analysis was performed across the IVBs. Driven by the chemical split from the RD reorganization in 2014, there is a disparity in number of products per branch for the IVBs, with IVB1 being responsible for more products than IVB2 and IVB3 combined. When considering number of actions received in FYs 19 and 20, while IVB1 still has ~20% more actions than IVB3, the greater discrepancy is between IVB1 and IVB2, where IVB1 has double the number of actions of IVB2. The large disparity does not appear to be justified based on difficulty of actions. To continue to address this workload imbalance, IVB1 will transfer cyclaniliprole to IVB3.	Establish a timeline for moving cyclaniliprole from IVB1 to IVB3			

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	Marion Johnson Debra Rate; Venus Eagle, Marianne Lewis, Tony Britten, Kimberly (and others)	OPPEL, eCSF, Salesforce Efforts – Integrated Workgroups aimed at enhancing electronic submission goals to improve quality of submissions and increase Program efficiencies	Continuation of eCSF Pilot. Further enhancement of eCSF tools	Continuing from Q1 + working to find better archival systems for eCSFs	Continuing from Q2 + development of CBI and record archival	Continuing from Q3 to complete all prior goals for implementation
Y	Marion Johnson Nathan Mellor Debra Rate Julie Breeden-Alemi	Reduced Risk Committee: In FY22, the Reduced Risk Committee Coordinator, Nathan Mellor and Steve Schaible from OPP/OD will continue to discuss with stakeholder/registrant= proposals to standardize the RR rationale.	Work to improve timeliness of RR decisions and response to registrant	Potential change in staffing to involve more rotations.	Work with DDs to transition new management participants on expectations.	Quantify and evaluate improvements over prior quarters
Y	Kerry Leifer, David Lieu	RD Contract Management <ul style="list-style-type: none"> Ensure the effective use of contractor resources within RD Manage the processes for sending tasks and receiving deliverables from contractor 	Quarterly briefing for RD IO	Quarterly briefing for RD IO	Quarterly briefing for RD IO	Quarterly briefing for RD IO
Y	ISB BC Raderrio Wilkins, Mick Yanchulis	Oversight of MERP contract	Bi-weekly status meetings with ITRMD/CCOE and DDMS Contractor Monthly check-In w/ITRMD AND RD to identify MERP	Bi-weekly status meetings with ITRMD/CCOE and DDMS Contractor Monthly check-In w/ITRMD AND RD to identify MERP	Monthly check-In w/ITRMD AND RD to identify MERP contract performance concerns	Provide contract dollar amounts for Task K of the DDMS (21-day and study indexing) of DDMS contract.

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
			contract performance Contract Officer (CO) and/or CCOE meet with MERP management to identify performance and discuss plans to remedy any outstanding performance concerns. Conduct spot checks of MERP to ensure performance according to the SOW	contract performance concerns Conduct spot checks of MERP to ensure performance according to the SOW	Conduct spot checks of MERP to ensure performance according to the SOW	Conduct spot checks of MERP to ensure performance according to the SOW
Y	Kerry Leifer, Shyam Mathur	Increasing lead time in completion of product chemistry reviews prior to PRIA date	Evaluate current workload and resources for product chemistry reviews	Pilot increasing lead time (from 7 days to 10 days) for subset of product chem actions	Based on pilot increase lead time from 7 days to 10 days for all product chem reviews	Extend lead time for product chemistry reviews to 14 days

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	Q1	Q2	Q3	Q4
Y	IO Tony	Annual PRIA Audit		Complete audit by finding responsive electronic documents and loading them on Sharepoint for Auditors.		
Y	IO Marietta, Paul, Tony	RD Workload Analysis Needed to right-size the workload in RD to the available resources, advocate for additional resources, develop RD priorities, and reset expectations of industry on asks and turnaround times	Present to Jake (October) Get permission to hire critical FTE vacancies (December)	Present to Michal (January) Communicate expectations to registrants (March)	Get permission to hire additional critical FTE vacancies (June)	Fill 15 FTE vacancies (September)
Y	ISB BC Raderrio Wilkins Mick Yanchulis Lee Sias	Test and implement Salesforce enhancements	ISB's Sales Force Trailblazers team to prioritize ISB's requested task to be implemented and/or updated in Sales Force	Track and monitor ISB's Sales Force processes for continuity of work	Track and monitor ISB's Sales Force processes for continuity of work	Track and monitor ISB's Sales Force processes for continuity of work

Additional Business Acumen Standing Work

In RD WP? (y/n)	TEAM AND LEAD(S)	PROJECT TITLE AND GOALS Why is this work important?	ADDITIONAL OUTPUTS FOR FY22
y	IVB1, HB, IO, IVB2, CITAB Jennifer Saunders, Bo Davis, Mindy Ondish, Jackie Herrick, David Lieu, Carmen Rodia	RD work on OPPT's Aventis contract: RD is buying into the Aventis Contract so they can help the division with administrative duties, such as loading dockets, NOFs, NORs, and Q&A for PPLS. This will reduce the workload for reviewers and allow them more time to work on actions. The task order should go into review by Q2, with the task order being signed in Q3.	